Asthma Clinical Trial
Official title:
The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics
Summary:
A picture is emerging of dendritic cells migrating through the blood to the airways following
allergen inhalation in atopic asthmatics. Although the Koh and McCarthy articles present
novel findings, both do not provide a comprehensive view of sputum DCs following allergen
challenge. Therefore, the proposed study will examine the kinetics of mDCs and pDCs in the
induced sputum of atopic asthmatics following inhalation of allergen.
Hypothesis:
Following allergen challenge, sputum myeloid and plasmacytoid DCs will migrate into the
airway lumen in atopic asthmatics during the timeframe of the late asthmatic response.
Objective:
The objective of this study is to examine the kinetics of dendritic cells in induced sputum
following allergen challenge in atopic asthmatic subjects.
Subjects will be put through two study periods. Each study period will consist of four visits
and will be separated by 2-4 weeks. On the first visit, subjects will undergo screening
procedures, including complete history and physical examination. In addition, methacholine
inhalation challenge and skin-prick testing will be preformed to assess airway
hyper-responsiveness and determine atopic status respectively. Lastly, sputum will be induced
before challenge (0 hrs) and peripheral blood will be collected. On the second visit,
subjects will inhale diluent or allergen and sputum will be collected 7 hours following
inhalation challenge. Next, on the third visit, subjects will return 24 hours following
inhalation challenge and sputum will be induced. On the final visit, subjects will return 72
hours following inhalation challenge and sputum will be collected, along with peripheral
blood.
Before the next study period begins, there will be a washout period of 2-4 weeks. On the
first visit of the second study period, a methacholine challenge will be performed to ensure
the return of PC20 to within one doubling dose of baseline values. Also, sputum will be
induced before challenge (0hrs) and peripheral blood will be collected. On the second visit,
subjects will inhale diluent or allergen and sputum will be collected 7hrs following
inhalation challenge. Next, on the third visit, subjects will return 24 hours following
inhalation challenge and sputum will be induced. On the final visit, subjects will return 72
hours following inhalation challenge and sputum will be collected, along with peripheral
blood.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|